{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:38:00Z","timestamp":1793410680698,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40265-026-02301-5","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T09:03:13Z","timestamp":1773478993000},"page":"627-643","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Metabolic Dysfunction-Associated Steatohepatitis (MASH)-Cirrhosis Clinical Trials: Lessons Learned and Future Directions"],"prefix":"10.1007","volume":"86","author":[{"given":"Rashmee","family":"Patil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winston","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Noureddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naim","family":"Alkhouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,14]]},"reference":[{"issue":"Suppl","key":"2301_CR1","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","volume":"31","author":"ZM Younossi","year":"2025","unstructured":"Younossi ZM, Kalligeros M, Henry L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2025;31(Suppl):S32\u201350.","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"2301_CR2","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335\u201347.","journal-title":"Hepatology"},{"issue":"7","key":"2301_CR3","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908\u201322.","journal-title":"Nat Med"},{"issue":"9","key":"2301_CR4","first-page":"929","volume":"30","author":"JC Fishman","year":"2024","unstructured":"Fishman JC, Qian C, Kim Y, Rochon H, Szabo SM, Sun R, et al. Cost burden of cirrhosis and liver disease progression in metabolic dysfunction-associated steatohepatitis: a US cohort study. J Manag Care Spec Pharm. 2024;30(9):929\u201341.","journal-title":"J Manag Care Spec Pharm"},{"issue":"12","key":"2301_CR5","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1080\/13543784.2020.1839888","volume":"29","author":"JPH Drenth","year":"2020","unstructured":"Drenth JPH, Schattenberg JM. The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success. Expert Opin Investig Drugs. 2020;29(12):1365\u201375.","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"2301_CR6","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41575-020-00408-y","volume":"18","author":"R Vuppalanchi","year":"2021","unstructured":"Vuppalanchi R, Noureddin M, Alkhouri N, Sanyal AJ. Therapeutic pipeline in nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol. 2021;18(6):373\u201392.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2301_CR7","unstructured":"Resmetirom reduces liver stiffness in MASH-compensated cirrhosis. https:\/\/ir.madrigalpharma.com\/news-releases\/news-release-details\/madrigal-announces-new-two-year-data-compensated-mash-cirrhosis."},{"key":"2301_CR8","unstructured":"Administration USFaD. Nonalcoholic steatohepatitis with compensated cirrhosis: developing drugs for treatment. Guidance for industry. Silver Spring, MD: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); 2019."},{"issue":"3","key":"2301_CR9","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","volume":"75","author":"European Association for the Study of the L.","year":"2021","unstructured":"European Association for the Study of the L. EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol. 2021;75(3):659\u201389.","journal-title":"J Hepatol"},{"issue":"3","key":"2301_CR10","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41591-023-02242-6","volume":"29","author":"SA Harrison","year":"2023","unstructured":"Harrison SA, Allen AM, Dubourg J, Noureddin M, Alkhouri N. Challenges and opportunities in NASH drug development. Nat Med. 2023;29(3):562\u201373.","journal-title":"Nat Med"},{"issue":"6","key":"2301_CR11","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/hep.30664","volume":"70","author":"AJ Sanyal","year":"2019","unstructured":"Sanyal AJ, Harrison SA, Ratziu V, Abdelmalek MF, Diehl AM, Caldwell S, et al. The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the Simtuzumab trials. Hepatology. 2019;70(6):1913\u201327.","journal-title":"Hepatology"},{"issue":"17","key":"2301_CR12","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","volume":"385","author":"AJ Sanyal","year":"2021","unstructured":"Sanyal AJ, Van Natta ML, Clark J, Neuschwander-Tetri BA, Diehl A, Dasarathy S, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med. 2021;385(17):1559\u201369.","journal-title":"N Engl J Med"},{"key":"2301_CR13","doi-asserted-by":"crossref","unstructured":"Harrison SA, Goodman Z, Jabbar A, Vemulapalli R, Younes ZH, Freilich B, et al. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis. J Hepatol. 2019.","DOI":"10.1016\/j.jhep.2019.11.024"},{"issue":"1","key":"2301_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","volume":"73","author":"SA Harrison","year":"2020","unstructured":"Harrison SA, Wong VW, Okanoue T, Bzowej N, Vuppalanchi R, Younes Z, et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. J Hepatol. 2020;73(1):26\u201339.","journal-title":"J Hepatol"},{"issue":"5","key":"2301_CR15","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1053\/j.gastro.2019.11.296","volume":"158","author":"N Chalasani","year":"2020","unstructured":"Chalasani N, Abdelmalek MF, Garcia-Tsao G, Vuppalanchi R, Alkhouri N, Rinella M, et al. Effects of Belapectin, an inhibitor of Galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension. Gastroenterology. 2020;158(5):1334-45 e5.","journal-title":"Gastroenterology"},{"issue":"5","key":"2301_CR16","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1053\/j.gastro.2020.12.003","volume":"160","author":"ZM Younossi","year":"2021","unstructured":"Younossi ZM, Anstee QM, Wai-Sun Wong V, Trauner M, Lawitz EJ, Harrison SA, et al. The association of histologic and noninvasive tests with adverse clinical and patient-reported outcomes in patients with advanced fibrosis due to nonalcoholic steatohepatitis. Gastroenterology. 2021;160(5):1608-19 e13.","journal-title":"Gastroenterology"},{"issue":"2","key":"2301_CR17","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","volume":"155","author":"E Vilar-Gomez","year":"2018","unstructured":"Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V, Castellanos M, Aller-de la Fuente R, Metwally M, et al. Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study. Gastroenterology. 2018;155(2):443-57 e17.","journal-title":"Gastroenterology"},{"issue":"9","key":"2301_CR18","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1111\/liv.15632","volume":"43","author":"BG Song","year":"2023","unstructured":"Song BG, Goh MJ, Kang W, Gwak GY, Paik YH, Choi MS, et al. Validation of non-invasive diagnosis of CSPH in patients with compensated advanced chronic liver disease according to Baveno VII. Liver Int. 2023;43(9):1966\u201374.","journal-title":"Liver Int"},{"issue":"15","key":"2301_CR19","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413\u201324.","journal-title":"N Engl J Med"},{"issue":"12","key":"2301_CR20","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1111\/dom.14160","volume":"22","author":"S Verma","year":"2020","unstructured":"Verma S, McGuire DK, Bain SC, Bhatt DL, Leiter LA, Mazer CD, et al. Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: results of the LEADER and SUSTAIN 6 trials. Diabetes Obes Metab. 2020;22(12):2487\u201392.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2301_CR21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cgh.2024.02.022","volume":"23","author":"SA Harrison","year":"2025","unstructured":"Harrison SA, Frias JP, Lucas KJ, Reiss G, Neff G, Bollepalli S, et al. Safety and efficacy of Efruxifermin in combination with a GLP-1 receptor agonist in patients with NASH\/MASH and type 2 diabetes in a randomized phase 2 study. Clin Gastroenterol Hepatol. 2025;23(1):103\u201313.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10181","key":"2301_CR22","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","volume":"393","author":"C Villanueva","year":"2019","unstructured":"Villanueva C, Albillos A, Genesca J, Garcia-Pagan JC, Calleja JL, Aracil C, et al. beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2019;393(10181):1597\u2013608.","journal-title":"Lancet"},{"issue":"10","key":"2301_CR23","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.cgh.2017.04.039","volume":"15","author":"RG Kim","year":"2017","unstructured":"Kim RG, Loomba R, Prokop LJ, Singh S. Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2017;15(10):1521-30 e8.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"2301_CR24","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.cgh.2023.06.004","volume":"22","author":"FS Yen","year":"2024","unstructured":"Yen FS, Hou MC, Cheng-Chung Wei J, Shih YH, Hsu CY, Hsu CC, et al. Glucagon-like Peptide-1 Receptor Agonist use in patients with liver cirrhosis and type 2 diabetes. Clin Gastroenterol Hepatol. 2024;22(6):1255-64 e18.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"24","key":"2301_CR25","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1056\/NEJMoa2502242","volume":"392","author":"M Noureddin","year":"2025","unstructured":"Noureddin M, Rinella ME, Chalasani NP, Neff GW, Lucas KJ, Rodriguez ME, et al. Efruxifermin in compensated liver cirrhosis caused by MASH. N Engl J Med. 2025;392(24):2413\u201324.","journal-title":"N Engl J Med"},{"key":"2301_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.601349","volume":"11","author":"E Henriksson","year":"2020","unstructured":"Henriksson E, Andersen B. FGF19 and FGF21 for the treatment of NASH-Two sides of the same coin? Differential and overlapping effects of FGF19 and FGF21 from mice to human. Front Endocrinol (Lausanne). 2020;11:601349.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"2301_CR27","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","volume":"27","author":"SA Harrison","year":"2021","unstructured":"Harrison SA, Ruane PJ, Freilich BL, Neff G, Patil R, Behling CA, et al. Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial. Nat Med. 2021;27(7):1262\u201371.","journal-title":"Nat Med"},{"issue":"1","key":"2301_CR28","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.cgh.2023.04.012","volume":"22","author":"MF Abdelmalek","year":"2024","unstructured":"Abdelmalek MF, Sanyal AJ, Nakajima A, Neuschwander-Tetri BA, Goodman ZD, Lawitz EJ, et al. Pegbelfermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis (FALCON 2): a randomized Phase 2b study. Clin Gastroenterol Hepatol. 2024;22(1):113-23 e9.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"2301_CR29","doi-asserted-by":"publisher","first-page":"60","DOI":"10.17925\/EE.2023.19.1.60","volume":"19","author":"G Karim","year":"2023","unstructured":"Karim G, Bansal MB. Resmetirom: an orally administered, smallmolecule, liver-directed, beta-selective THR agonist for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. touchREV Endocrinol. 2023;19(1):60\u201370.","journal-title":"touchREV Endocrinol"},{"key":"2301_CR30","unstructured":"Therapeutics A. SYNCHRONY outcomes study: efruxifermin (EFX) in compensated cirrhosis due to MASH. 2024."},{"key":"2301_CR31","unstructured":"Therapeutics A. Akero initiates phase 3 SYNCHRONY outcomes study in MASH cirrhosis. 2023. https:\/\/akerotx.com\/news\/akero-initiates-phase-3-synchrony-outcomes-study-in-mash-cirrhosis\/."},{"issue":"2","key":"2301_CR32","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1124\/jpet.123.001618","volume":"387","author":"M Rosenstock","year":"2023","unstructured":"Rosenstock M, Tseng L, Pierce A, Offman E, Chen CY, Charlton RW, et al. The novel GlycoPEGylated FGF21 analog Pegozafermin activates human FGF receptors and improves metabolic and liver outcomes in diabetic monkeys and healthy human volunteers. J Pharmacol Exp Ther. 2023;387(2):204\u201313.","journal-title":"J Pharmacol Exp Ther"},{"key":"2301_CR33","unstructured":"89bio I. ENLIGHTEN-C: a study of pegozafermin in subjects with MASH and compensated cirrhosis. NCT06172796; 2024."},{"key":"2301_CR34","unstructured":"89bio I. 89bio announces ENLIGHTEN-C phase 3 study for pegozafermin in MASH cirrhosis. 2024. https:\/\/www.89bio.com\/news\/89bio-announces-enlighten-c-phase-3-study."},{"key":"2301_CR35","unstructured":"89bio I. Corporate presentation Q1 2024: ENLIGHTEN-OUTCOMES trial strategy. 2024. https:\/\/www.89bio.com\/investors\/presentations."},{"issue":"10","key":"2301_CR36","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1002\/hep4.1108","volume":"1","author":"M Zhou","year":"2017","unstructured":"Zhou M, Learned RM, Rossi SJ, DePaoli AM, Tian H, Ling L. Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice. Hepatol Commun. 2017;1(10):1024\u201342.","journal-title":"Hepatol Commun"},{"issue":"1","key":"2301_CR37","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1053\/j.gastro.2018.09.021","volume":"156","author":"R Loomba","year":"2019","unstructured":"Loomba R, Sanyal AJ, Kowdley KV, Terrault N, Chalasani NP, Abdelmalek MF, et al. Factors associated with histologic response in adult patients with nonalcoholic steatohepatitis. Gastroenterology. 2019;156(1):88-95 e5.","journal-title":"Gastroenterology"},{"issue":"7","key":"2301_CR38","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S2468-1253(22)00017-6","volume":"7","author":"SA Harrison","year":"2022","unstructured":"Harrison SA, Abdelmalek MF, Neff G, Gunn N, Guy CD, Alkhouri N, et al. Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2\/3): a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterol Hepatol. 2022;7(7):603\u201316.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"2301_CR39","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.2337\/db12-0222","volume":"62","author":"NN Pejnovic","year":"2013","unstructured":"Pejnovic NN, Pantic JM, Jovanovic IP, Radosavljevic GD, Milovanovic MZ, Nikolic IG, et al. Galectin-3 deficiency accelerates high-fat diet-induced obesity and amplifies inflammation in adipose tissue and pancreatic islets. Diabetes. 2013;62(6):1932\u201344.","journal-title":"Diabetes"},{"issue":"3","key":"2301_CR40","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1097\/HEP.0000000000000607","volume":"79","author":"ME Rinella","year":"2024","unstructured":"Rinella ME, Lieu HD, Kowdley KV, Goodman ZD, Alkhouri N, Lawitz E, et al. A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis. Hepatology. 2024;79(3):674\u201389.","journal-title":"Hepatology"},{"issue":"2","key":"2301_CR41","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/hep.31204","volume":"72","author":"RA Sinha","year":"2020","unstructured":"Sinha RA, Bruinstroop E, Singh BK, Yen PM. Thyroid hormones and thyromimetics: a new approach to nonalcoholic steatohepatitis? Hepatology. 2020;72(2):770\u20131.","journal-title":"Hepatology"},{"issue":"4","key":"2301_CR42","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41573-021-00367-2","volume":"21","author":"B Batchuluun","year":"2022","unstructured":"Batchuluun B, Pinkosky SL, Steinberg GR. Lipogenesis inhibitors: therapeutic opportunities and challenges. Nat Rev Drug Discov. 2022;21(4):283\u2013305.","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"2301_CR43","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1016\/j.cgh.2024.07.003","volume":"22","author":"M Noureddin","year":"2024","unstructured":"Noureddin M, Charlton MR, Harrison SA, Bansal MB, Alkhouri N, Loomba R, et al. Expert panel recommendations: practical clinical applications for initiating and monitoring Resmetirom in patients with MASH\/NASH and moderate to noncirrhotic advanced fibrosis. Clin Gastroenterol Hepatol. 2024;22(12):2367\u201377.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"2301_CR44","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/HEP.0000000000001112","volume":"81","author":"VL Chen","year":"2025","unstructured":"Chen VL, Morgan TR, Rotman Y, Patton HM, Cusi K, Kanwal F, et al. Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance. Hepatology. 2025;81(1):312\u201320.","journal-title":"Hepatology"},{"issue":"4","key":"2301_CR45","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","volume":"27","author":"DJ Drucker","year":"2018","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740\u201356.","journal-title":"Cell Metab"},{"issue":"Suppl 1","key":"2301_CR46","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.13129","volume":"20","author":"MA Nauck","year":"2018","unstructured":"Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018;20(Suppl 1):5\u201321.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"2301_CR47","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","volume":"8","author":"R Loomba","year":"2023","unstructured":"Loomba R, Abdelmalek MF, Armstrong MJ, Jara M, Kjaer MS, Krarup N, et al. Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(6):511\u201322.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2301_CR48","doi-asserted-by":"crossref","unstructured":"Bansal MB, Patton H, Morgan TR, Carr RM, Dranoff JA, Allen AM. Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD practice guidance. Hepatology. 2025.","DOI":"10.1097\/HEP.0000000000001608"},{"issue":"3","key":"2301_CR49","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41366-024-01473-y","volume":"49","author":"E Melson","year":"2025","unstructured":"Melson E, Ashraf U, Papamargaritis D, Davies MJ. What is the pipeline for future medications for obesity? Int J Obes (Lond). 2025;49(3):433\u201351.","journal-title":"Int J Obes (Lond)"},{"key":"2301_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2020.105881","volume":"130","author":"RJ Slack","year":"2021","unstructured":"Slack RJ, Mills R, Mackinnon AC. The therapeutic potential of galectin-3 inhibition in fibrotic disease. Int J Biochem Cell Biol. 2021;130:105881.","journal-title":"Int J Biochem Cell Biol"},{"key":"2301_CR51","unstructured":"Galectin Therapeutics Reports Significant Reduction in New Varices with Belapectin in U.S. Patient Population from the NAVIGATE Trial. https:\/\/investor.galectintherapeutics.com\/news-releases\/news-release-details\/galectin-therapeutics-reports-significant-reduction-new-varices."},{"issue":"5","key":"2301_CR52","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1038\/s41401-021-00832-z","volume":"43","author":"BE Harvey","year":"2022","unstructured":"Harvey BE. NASH: regulatory considerations for clinical drug development and U.S. FDA approval. Acta Pharmacol Sin. 2022;43(5):1210\u20134.","journal-title":"Acta Pharmacol Sin"},{"issue":"6","key":"2301_CR53","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s40265-024-02045-0","volume":"84","author":"SJ Keam","year":"2024","unstructured":"Keam SJ. Resmetirom: first approval. Drugs. 2024;84(6):729\u201335.","journal-title":"Drugs"},{"key":"2301_CR54","unstructured":"Efruxifermin Shows Long-Term Promise in MASH-Related Cirrhosis Despite Missing Primary Endpoint in Phase IIb Trial."},{"key":"2301_CR55","unstructured":"Two Phase 3 pegozafermin trials for severe fatty liver disease enrolling."},{"issue":"11-12","key":"2301_CR56","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1111\/apt.18331","volume":"60","author":"PN Newsome","year":"2024","unstructured":"Newsome PN, Sanyal AJ, Engebretsen KA, Kliers I, Ostergaard L, Vanni D, et al. Semaglutide 2.4 mg in participants with metabolic dysfunction-associated steatohepatitis: baseline characteristics and design of the phase 3 ESSENCE trial. Aliment Pharmacol Ther. 2024;60(11\u201312):1525\u201333.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"2301_CR57","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa2401755","volume":"391","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E, et al. A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med. 2024;391(4):311\u20139.","journal-title":"N Engl J Med"},{"key":"2301_CR58","unstructured":"LIVERAGE\u2122: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH\/MASH Who Have Moderate or Advanced Liver Fibrosis."},{"key":"2301_CR59","unstructured":"Belapectin may help reduce liver scarring in those with severe MASH. liverdiseasenews.com."},{"issue":"1","key":"2301_CR60","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/apt.17734","volume":"59","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Ratziu V, Anstee QM, Noureddin M, Sanyal AJ, Schattenberg JM, et al. Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis. Aliment Pharmacol Ther. 2024;59(1):51\u201363.","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02301-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02301-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02301-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T05:02:25Z","timestamp":1777006945000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02301-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,14]]},"references-count":60,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2301"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02301-5","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,14]]},"assertion":[{"value":"3 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received to support the writing of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Rashmee Patil has received research funding via investigator grants from: Akero Therapeutics, Boehringer Ingelheim, Eli Lilly, Madrigal Pharmaceuticals, Merck, Novo Nordisk, 89Bio, and Inventiva. She has received consulting\/advisory fees from Boehringer Ingelheim and Novo Nordisk and is on the speaker\u2019s bureau for Novo Nordisk and Madrigal Pharmaceuticals. Winston Dunn reports grants from 89bio, Inc; NATiV3; Novo Nordisk; and Madrigal Pharmaceuticals. He is a member of the speakers\u2019 bureaus for Novo Nordisk and Madrigal Pharmaceuticals and serves on an advisory board for Ipsen Biopharmaceuticals. Mazen Noureddin declares Advisory Board\/Consulting: Akero, Altimmune, Alligos, AstraZeneca, BI, Boston Pharma, Curve bioscience, Daiichi Sankyo, GSK, Histoindex, Kryia , Lilly, Madrigal, Merck, Neuraly, Novo Nordisk, OPKO, Rivus, Sagimet, and Takeda. Principal Investigator for a Drug Study: Allergan, Altimmune, Akero, BI, BMS, Boston Pharma, Conatus, Corcept, Gilead, Galectin, Genfit, GSK, Kowa, Enanta, Madrigal, Lilly, Merck, Novartis, Novo Nordisk, Rivus, Shire, Takeda, Terns, Viking, and Zydus. Stockholder: OPKO, Kryia and Akero. Speaking bureau: Madrigal and Novo Nordisk. Naim Alkhouri. has received grant\/research support from 89bio, Akero Therapeutics, Arbutus Biopharma, AstraZeneca, BioAge, Boehringer Ingelheim, Bristol Myers Squibb, Corcept Therapeutics, Galectin Therapeutics, Genentech, Gilead Sciences, Hepagene Therapeutics, Intercept Pharmaceuticals, Inventiva Pharma, Ionis Pharmaceuticals, Ipsen, Lilly, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, NorthSea Therapeutics, Novo Nordisk, Perspectum, Pfizer, PharmaIN, Poxel, Regeneron, Viking Therapeutics, and Zydus Pharmaceuticals; reports speaker\u2019s fees from AbbVie, AstraZeneca, Echosens, Gilead Sciences, Ipsen, Madrigal Pharmaceuticals, Novo Nordisk, and Perspectum; and reports consulting for 89bio, AbbVie, Akero, Boehringer Ingelheim, Echosens, Fibronostics, Gilead Sciences, HistoIndex, Intercept Pharmaceuticals, Ipsen, LiverRight, Madrigal Pharmaceuticals, NorthSea Therapeutics, Novo Nordisk, Perspectum, Pfizer, Regeneron, and Sonicy Incytes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable. This manuscript is a narrative review and does not include original datasets.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable. This study did not involve human participants or animal experiments.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"N.A. and M.N. contributed to the conception and design of the review. R.P. and W.D. drafted the initial manuscript. All authors contributed to critical revision of the manuscript for important intellectual content and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}